EsoBiotec SA
9.4 FTEThe score of EsoBiotec shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +146 % Total assets +126 % Headcount (avg FTE) +34 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →EsoBiotec's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 07 Jul 2026
- Year ended 31 Dec 2024filed on 08 Jul 2025
- Year ended 31 Dec 2023filed on 27 Jun 2024
- Year ended 31 Dec 2022filed on 29 Jun 2023
- Year ended 31 Dec 2021filed on 05 Jul 2022
EsoBiotec's financial analysis
- Solvency75.3%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of EsoBiotec
EsoBiotec's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0756.885.159
- VAT number
- BE0756885159
- Peppol
- Registered · 0208:0756885159 · as of 30 Oct 2026
- Legal form
- SA
- Incorporated
- 22 Oct 2020
- Registered office
- 1435 Mont-Saint-Guibert
- Size
- Micro · 9.4 FTE
- Latest accounts
- 2025 · filed on 07 Jul 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
EsoBiotec (SA) has been based in Mont-Saint-Guibert since 2020, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of €7.73m and equity of €12.4m; its revenue is not published. With 9.4 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 75.3%, above the median of its sector (58.2%).
Companies similar to EsoBiotec
Companies in the same business, of comparable size and area, outside its group.
- ViiV Healthcare Research and experimental development on natural sciences and engineering Wavre · balance sheet €17.0m
- ECOO Innovation Research and experimental development on natural sciences and engineering Houthalen-Helchteren · balance sheet €18.6m
- Oystershell Research and experimental development on natural sciences and engineering Merelbeke-Melle · balance sheet €32.7m
- LabCorp Research and experimental development on natural sciences and engineering Mechelen · balance sheet €36.1m
- Baxter R and D Europe Research and experimental development on natural sciences and engineering Lessines · balance sheet €52.7m
- Biotalys Research and experimental development on natural sciences and engineering Ghent · balance sheet €16.3m
- Nanocyl Research and experimental development on natural sciences and engineering Sambreville · balance sheet €13.2m
- Ogeda Research and experimental development on natural sciences and engineering Vilvoorde · balance sheet €53.5m
Frequently asked questions about EsoBiotec
What is the revenue of EsoBiotec?
EsoBiotec files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of EsoBiotec?
In Belgium, the VAT number is the company number prefixed with BE: BE0756885159 for EsoBiotec, if the company is VAT-registered. Its company number (CBE) is 0756.885.159.
Where is the registered office of EsoBiotec?
According to the CBE register, the registered office of EsoBiotec is in 1435 Mont-Saint-Guibert.
What is the equity of EsoBiotec?
At the close of the 2025 financial year, the equity of EsoBiotec amounts to 12,414,984 €, a solvency of 75.3% of total assets.
How many people work at EsoBiotec?
9.4 full-time equivalents on average according to the 2025 social balance sheet.
Who manages EsoBiotec?
The register lists 3 active mandates at EsoBiotec. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of EsoBiotec
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →